Phase 1 results from Ebola vaccines released
The Oxford Vaccines Group conducted the study with 72 health volunteer subjects. These subjects were randomly assigned to four different groups and randomly received either the placebo or the vaccine regimen. On day 1, patients received a priming dose of MVA-BN Filo or Ad26.ZEBOV. After 28 or 56 days, patients received booster doses from the other vaccine. Fifteen patients involved in an open label arm also received a shorter prime-boost interval of Ad26.ZEBOV and MVA-BN Filo at 14 days.
Preliminary results suggest that the prime-boost vaccine is immunogenic; both of the vaccines enhanced the immune response against the vaccine.
"These preliminary Phase 1 results are encouraging as they confirm the ability of MVA-BN to boost the immune response, which is crucial for obtaining long-term protection and designing a suitable vaccination strategy for future outbreaks,” said Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic. “We are pleased to continue our collaboration with Janssen, which is demonstrating leadership by continuing its efforts to improve the manufacturing capabilities, establishing the necessary infrastructure and developing strategies for deployment of vaccines for the current and future outbreaks in Africa."
The results were presented by Janssen at a recent meeting with the United States Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee.